Sigyn Therapeutics annual return on equity
2015
Sigyn Therapeutics Return on Equity (ROE) Growth & History (SIGY)
Sigyn Therapeutics's return on equity was −30,924.65% for fiscal 2015.
View full Sigyn Therapeutics company overviewSigyn Therapeutics annual return on equity history
| Fiscal year | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| 2015 | 2015-12-31 | −30,924.65% | — |
Sigyn Therapeutics quarterly return on equity
Q3.15
Q2.18
Q1.21
Q2.21
Q3.21
Q4.21
| Fiscal quarter | Period ended | Return on equity | Change (percentage points) |
|---|---|---|---|
| Q4 2021 | 2021-12-31 | −2,620.82% | — |
| Q3 2021 | 2021-09-30 | −99.73% | — |
| Q2 2021 | 2021-06-30 | −144.92% | — |
| Q1 2021 | 2021-03-31 | −4,878.81% | — |
| Q2 2018 | 2018-06-30 | −975.35% | — |
| Q3 2015 | 2015-09-30 | −1,345.21% | — |
Sigyn Therapeutics return on equity trends
The latest reported quarter, Q4 2021, shows −2,620.82%.
About the metric
What return on equity (ROE) means
Return on equity (ROE) measures how much net income a company generates relative to shareholders’ equity. It can help evaluate how efficiently equity capital is used, but unusually high or negative values may reflect leverage, losses, or a small equity base.
Calculation and source
How return on equity is calculated
TickerStat calculates ROE as SEC-reported net income divided by average stockholders’ equity at the beginning and end of the fiscal period. Periods with missing or non-positive average equity are omitted. Quarterly ROE uses quarterly net income and is not annualized. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Sigyn Therapeutics source filings ↗